End-of-day quote
Nasdaq
06:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
2.5
USD
|
-13.49%
|
|
-5.66%
|
-38.34%
|
Fiscal Period: Junio |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
48.79
|
9.857
|
6.475
|
7.11
|
-
|
-
|
Enterprise Value (EV)
1 |
48.79
|
9.857
|
6.475
|
7.11
|
7.11
|
7.11
|
P/E ratio
|
-5.79
x
|
-1.16
x
|
-0.26
x
|
-0.68
x
|
-0.73
x
|
-1.98
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
22.5
x
|
5.15
x
|
1.7
x
|
0.75
x
|
0.37
x
|
EV / Revenue
|
-
|
22.5
x
|
5.15
x
|
1.7
x
|
0.75
x
|
0.37
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
51.6
|
62
|
194
|
2,844
|
-
|
-
|
Reference price
2 |
945.6
|
158.9
|
33.36
|
2.500
|
2.500
|
2.500
|
Announcement Date
|
8/11/21
|
8/31/22
|
8/23/23
|
-
|
-
|
-
|
Fiscal Period: June |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.4372
|
1.257
|
4.18
|
9.428
|
19.22
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-8.337
|
-12.6
|
-8.49
|
-6.072
|
-0.7805
|
Operating Margin
|
-
|
-1,907.1%
|
-1,002.11%
|
-203.11%
|
-64.4%
|
-4.06%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-8.485
|
-8.306
|
-10.63
|
-8.52
|
-6.142
|
-0.8555
|
Net margin
|
-
|
-1,900.05%
|
-845.89%
|
-203.83%
|
-65.15%
|
-4.45%
|
EPS
2 |
-163.2
|
-136.8
|
-127.0
|
-3.670
|
-3.445
|
-1.265
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/11/21
|
8/31/22
|
8/23/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
0.1778
|
0.1925
|
0.0669
|
-
|
0.3567
|
0.4571
|
0.4431
|
0.7961
|
0.7641
|
0.8238
|
1.43
|
1.75
|
2.25
|
3.33
|
4.29
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.467
|
-1.343
|
-2.088
|
-
|
-2.131
|
-6.543
|
-2.702
|
-2.526
|
-1.991
|
-2.954
|
-1.79
|
-2.37
|
-1.47
|
-1.28
|
-0.54
|
Operating Margin
|
-1,949.85%
|
-697.57%
|
-3,123.08%
|
-
|
-597.45%
|
-1,431.63%
|
-609.85%
|
-317.35%
|
-260.63%
|
-358.55%
|
-125.17%
|
-135.43%
|
-65.33%
|
-38.44%
|
-12.59%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-3.464
|
-1.335
|
-2.078
|
-1.208
|
-0.4206
|
-6.344
|
-2.659
|
-2.425
|
-1.97
|
-2.978
|
-1.78
|
-2.36
|
-1.46
|
-1.27
|
-0.53
|
Net margin
|
-1,948.26%
|
-693.64%
|
-3,108.23%
|
-
|
-117.92%
|
-1,387.98%
|
-600.02%
|
-304.64%
|
-257.79%
|
-361.46%
|
-124.48%
|
-134.86%
|
-64.89%
|
-38.14%
|
-12.35%
|
EPS
2 |
-55.20
|
-21.60
|
-33.60
|
-19.20
|
-5.520
|
-68.64
|
-22.92
|
-12.48
|
-2.070
|
-1.430
|
-0.5100
|
-0.5300
|
-0.3200
|
-0.2800
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
5/11/22
|
8/31/22
|
11/9/22
|
2/14/23
|
5/11/23
|
8/23/23
|
11/8/23
|
2/9/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/11/21
|
8/31/22
|
8/23/23
|
-
|
-
|
-
|
Average target price
42
USD Spread / Average Target +1,580.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.34% | 7.11M | | -19.60% | 10.94B | | +64.70% | 3.75B | | -31.09% | 2.27B | | -10.77% | 2.25B | | -26.86% | 1.54B | | +35.42% | 1.18B | | -2.40% | 754M | | -35.10% | 469M | | +14.91% | 340M |
Bio Diagnostics & Testing
|